published meta-analysis   sensitivity analysis   studies

zinc plus vitamin c in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsThomas (vitamin c plus zinc), 2021 3.54 [0.16; 80.27] 3.54[0.16; 80.27]Thomas (vitamin c plus zinc), 202110%108NAnot evaluable clinical improvementdetailed resultsThomas (vitamin c plus zinc), 2021 0.85 [0.27; 2.65] 0.85[0.27; 2.65]Thomas (vitamin c plus zinc), 202110%108NAnot evaluable hospitalizationdetailed resultsThomas (vitamin c plus zinc), 2021 2.15 [0.53; 8.80] 2.15[0.53; 8.80]Thomas (vitamin c plus zinc), 202110%108NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-04-24 06:28 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 885 - roots T: 290